CPT code 87483 represents a laboratory molecular diagnostic test that performs multiplex amplified probe detection of multiple central nervous system (CNS) pathogens, potentially including multiplex reverse transcription for RNA targets. This code is nationally relevant because accurate, rapid identification of CNS pathogens drives clinical decisions for conditions such as meningitis and encephalitis and affects inpatient management, antimicrobial stewardship, and public health reporting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a succinct overview of what the code covers clinically and operationally, typical sites of service, and common modifiers in use. The publication provides benchmarks and payer-specific coverage context where available, summarizes clinical utility and testing workflow implications, and highlights recent policy or coding clarifications that affect billing and claims adjudication.

This summary is intended to orient laboratory directors, coding professionals, and hospital billing teams to the clinical role of the test, payer coverage landscape, and the types of documentation and claim components commonly associated with multiplex CNS pathogen molecular testing. Data not available in the input will be noted in relevant sections.